StockData
Rani Therapeutics Holdings, Inc. logo

Rani Therapeutics Holdings, Inc. (RANI) company profile

RANINasdaqPharmaceutical PreparationsFiscal year ends December 31
Số liệu tài chính tới Q2 năm tài chính 2026, quý kết thúc ngày Jun 30, 2026Last filing: 10-Q on Nov 9, 2026Score 3/3043% above fair value
$0.56+0.02 (+3.54%)

Close on Nov 17, 2026Market cap $77.98MP/E –Yield –

About Rani Therapeutics

Pharmaceutical Preparations, SIC 2834

Rani Therapeutics is a clinical-stage biotherapeutics enterprise that develops oral delivery technologies for biologics and drugs, designed to replace traditional subcutaneous and intravenous injections. The company focuses on its proprietary, drug-agnostic RaniPill platform, which includes the RaniPill GO microtablet system and the RaniPill HC high-capacity liquid formulation capsule. Its therapeutic pipeline spans multiple indications, including obesity, inflammatory disorders, and rare diseases, featuring active candidates such as RT-114, RT-116, RT-111, and RT-117. Intended customers and commercial targets comprise partner biopharmaceutical firms seeking oral delivery mechanisms for proprietary compounds, alongside eventual end-users including patients, prescribing clinicians, and healthcare networks.

The business conducts preclinical evaluation and automated pilot manufacturing in-house while engaging external engineering contractors and global component suppliers. Clinical development activities and trial cohorts have operated across locations including Australia, with planned future commercialization spanning the United States, Europe, and Asia. Corporate headquarters and physical facility locations are not detailed in the provided excerpt, nor are formal founding dates or web domains specified.

Summary of the business section of Rani Therapeutics's latest annual report, written by StockData.

Company profile

Company

Legal name
Rani Therapeutics Holdings, Inc.
Headquarters
San Jose, CA
Address
2051 Ringwood Avenue 95131
Phone
(408) 457-3700
Employees
69, Dec 31, 2025
Industry
Pharmaceutical Preparations
Fiscal year ends
December 31
Auditor
Marcum LLP, San Francisco, California

Stock & identifiers

Ticker
RANI
Exchange
Nasdaq
IPO date
Aug 2, 2021
Shares outstanding
139M, Jul 31, 2026
Public float
$65.00M, Jun 30, 2025
Filer category
Non-accelerated filer<br>Smaller reporting company<br>Emerging growth company
SEC CIK
1856725
CUSIP
753018100
ISIN
US7530181004
FIGI
BBG011R6PZ44
Share class FIGI
BBG011R6PZZ0
EIN
86-3114789

Executives and directors

Officers and directors who filed ownership reports (Forms 3, 4, 5) in the last two years

NamePositionShares owned
Talat ImranChief Executive Officer, Director474,151
Alireza JavadiChief Technical Officer9,071
Nicholas MaestasChief Financial Officer–
Kate McKinleyChief Business Officer17,960
Svai S. SanfordChief Financial Officer258,597
Mir HashimChief Scientific Officer445,250
Michelle GilsonDirector–
Mir A. ImranDirector24,853,526
Vasudev Jaiprakash BaileyDirector–
Dennis A. AusielloDirector–
Jean Luc ButelDirector50,500
Abraham BassanDirector–
Lisa Ann RomettyDirector–
Maulik NanavatyDirector64,345
Andrew FarquharsonDirector509,318
Laureen DebuonoDirector–

Executive compensation, fiscal 2025

Summary compensation table from the latest proxy statement

ExecutiveSalaryBonusOption awardsIncentive payTotalvs. prior year
Talat Imran
Chief Executive Officer
$198.33K–$502.18K$351.60K$1.05M-65%
Svai Sanford
Chief Financial Officer
$392.71K$139.00K$154.99K$259.70K$946.40K-27%
Kate McKinley
Chief Business Officer
$370.47K$130.00K$201.57K$241.90K$943.94K-25%

Stock and option awards are grant-date fair values, not realized pay. “Other” includes pension value changes and all other compensation. Source proxy statement.

IPO

From the final prospectus (Form 424B4) and the first day of trading

Offering

Type
Initial public offering
Final prospectus filed
Aug 2, 2021
Offer price
$11.00
Securities offered
6,666,667
Gross proceeds
$73.33M
Exchange
Nasdaq
First trading day
Jul 30, 2021
First-day close
$11.000.0%
Lock-up ends (est.)
Jan 26, 2022

“ntinuing LLC Owners, through their ownership of Class B common stock, collectively will hold no economic interest in Rani Holdings and the remaining 94.0% of the voting power in Rani Holdings, at the initial public offering price of $11.00 per share.”

Lock-up end is estimated as 180 days after the first trading day; the prospectus sets the actual terms.

Employees

Headcount reported in annual reports

“As of December 31, 2025, we had 69 full-time employees and two part-time employees.”

Corporate history

Events identified from SEC filings

See a number that looks wrong?